[Federal Register Volume 59, Number 227 (Monday, November 28, 1994)]
[Unknown Section]
[Page ]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-29133]


[Federal Register: November 28, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE
National Technical Information Service


Prospective Grant of Exclusive Patent License

    This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 
404.7(a)(1)(i) that the National Technical Information Service (NTIS), 
U.S. Department of Commerce, is contemplating the grant of an exclusive 
license in the United States of America to practice the inventions 
embodied in the following series of U.S. Patents: 4,127,528, 4,127,518, 
4,127,535, 4,127,534, 4,127,531, 4,127,532, 4,127,533, 4,139,504, 
4,127,541, 4,127,523, 4,127,524, 4,127,525, 4,127,526, 4,127,527, 
4,127,519, 4,127,520, 4,127,529, 4,127,530, 4,127,517, 4,127,536, 
4,127,537, 4,127,538, 4,127,539, 4,127,540, 4,127,521, 4,127,522, 
4,180,501, 4,213,968, and 4,312,857, to Trans-Neuro, Inc., having a 
place of business in Wilmette, Illinois. The patent rights in these 
inventions have been assigned to the United States of America.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
While the primary purpose of this notice is to announce NTIS' intent to 
grant an exclusive license to practice the noted patents, it also 
serves to publish said patents' availability for licensing in 
accordance with law. The prospective exclusive license may be granted 
unless, within 90 days from the date of this published notice, NTIS 
receives written evidence and argument which establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR 404.7.
    The series of related inventions expressed in the patents cited 
above describe various peptides, endorphins and enkephalins believed to 
be beneficial in the therapeutic treatment of a range of conditions 
believed to be caused by defective brain mechanisms, including various 
forms of mental illness.
    Copies of the instant patents are available from the Commissioner 
of Patents and Trademarks, Box 9, Washington, DC at a cost of $3.00 
each.
    Any inquiries and comments relating to the contemplated license 
must be submitted to Neil L. Mark, Office of Federal Patent Licensing, 
NTIS, Box 1423, Springfield, Virginia 22151. Properly filed competing 
license applications received by the NTIS in response to this notice 
will be considered as objections to the grant of the contemplated 
license.
Douglas J. Campion,
Director, Office of Federal Patent Licensing.
[FR Doc. 94-29133 Filed 11-25-94; 8:45 am]
BILLING CODE 3510-04-M